Gilead’s Lucrative Hep C Patents Face PTAB Assault

Media Article 26 Oct 2017

A nonprofit group focused on drug competition is attacking six key patents for Gilead Sciences Inc.’s blockbuster portfolio of hepatitis C drugs, telling the Patent Trial and Appeal Board that a crucial active ingredient was created using obvious scientific approaches.

The Initiative for Medicines, Access & Knowledge Inc. said Wednesday that it filed petitions for inter partes review at the PTAB in hopes of clearing the way sooner for generic versions of Gilead’s three hep C drugs: Sovaldi, Harvoni and Epclusa.

Partner with us now to build
a more just and equitable
medicine system for all.